

**Supplemental Table 4. Intracranial efficacy in patients with at least one measurable CNS lesion, excluding those who stopped brain radiotherapy <8 weeks before starting lorlatinib**

	≥1 prior second-generation ALK TKI (EXP3B–5)	1 prior second-generation ALK TKI (EXP3B)	≥2 prior ALK TKIs (EXP4–5)
<i>N</i>	50	7	43
ORR, <i>n</i> (%)	29 (58.0)	5 (71.4)	24 (55.8)
95% CI	43.2–71.8	29.0–96.3	39.9–70.9
Best overall IC response, <i>n</i> (%)			
Complete response	12 (24.0)	2 (28.6)	10 (23.3)
Partial response	17 (34.0)	3 (42.9)	14 (32.6)
Stable disease / no response	13 (26.0)	0	13 (30.2)
Progressive disease	5 (10.0)	1 (14.3)	4 (9.3)
Indeterminate	3 (6.0)	1 (14.3)	2 (4.7)
Duration of IC objective response, <sup>a</sup> months			
<i>N</i>	29	5	24
Median	11.1	4.2	12.4
95% CI	6.0–37.1	4.1–37.1	6.9–NE

ALK, anaplastic lymphoma kinase; CI, confidence interval; CNS, central nervous system; EXP, expansion cohort; IC, intracranial; NE, not estimable; ORR, objective response rate; TKI, tyrosine kinase inhibitor.

<sup>a</sup> Kaplan–Meier estimates; CIs were derived using the Brookmeyer Crowley method.